Standard Curve
Example of Human FBLN7 standard curve in Assay Diluent EG2H5. Plotted are the background-subtracted data.
This standard curve is provided for demonstration only.
Human FBLN7 OneStep ELISA Kit
Human FBLN7 OneStep ELISA Kit
Price:
Regular price
$250 USD
Regular price
Sale price
$250 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Immunogen | Recombinant Protein |
| Antibody Type | Recombinant mAb |
| Reactivity | Hu |
| Purification | Protein A |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8°C as supplied. |
Kit
| Precision | Intra-assay: 1.9%； Inter-assay: 2.5% |
| Sample type | Serum; Citrate plasma; Heparin Plasma; Cell Culture Supernatant |
| Assay type | Sandwich |
| Sensitivity | 0.01 ng/mL |
| Range | 0.08 ng/mL -5 ng/mL |
| Recovery | Serum: 93% Citrate plasma: 94% Heparin Plasma: 95% Cell Culture Supernatant: 89% |
| Assay time | 90 minutes |
| Species reactivity | Hu |
Background
Human FBLN7 (Fibulin-7) is a secreted extracellular matrix glycoprotein and a recently identified member of the Fibulin family, initially discovered in developing tooth tissue and expressed in a tissue-specific manner in cartilage, eye, placenta, muscle, and heart. It contains multiple functional domains that mediate interactions with extracellular matrix components and cell surface receptors. Functionally, FBLN7 is implicated in diverse pathophysiological processes: it promotes adipose tissue fibrosis in obesity via TSP1-mediated amplification of TGF-β/Smad signaling and mediates pathological cardiac remodeling through EGFR activation; it is overexpressed in glioblastoma and regulates tumor neovascularization via angiopoietin-1, while its C-terminal fragment inhibits angiogenesis and modulates macrophage function to suppress tumor growth; it also regulates neutrophil migration and exacerbates oxalate calcium-induced acute kidney injury. Genetically, FBLN7 deficiency is associated with 2q13 microdeletion syndrome, congenital heart defects, craniofacial anomalies, and a progressive skeletal dysplasia with cerebellar atrophy and ichthyosis. Given its multifaceted roles in fibrosis, tumor angiogenesis, and inflammation, FBLN7 represents a research target of potential therapeutic value, particularly its C-terminal fragment, which offers a promising direction for peptide-based therapeutic development.
Picture
Picture
ELISA
Dilution Linearity
The concentrations of Human FBLN7 were measured and interpolated from the target standard curves and corrected for sample dilution.
The leftmost bar in the graph shows biological samples diluted in Assay Diluent to 100% concentration. "undiluted" was defined as 100% biological sample. The subsequent bars represent two-fold serial dilutions of this reference. The mean target concentration was determined to be 2.45 ng/mL in Mouse heart tissue culture supernatant.
Spike Recovery
The recovery of Human FBLN7 was evaluated in activated samples spiked with concentrations spanning the entire assay range.
Spike RecoveryRecovery of Human FBLN7 was assessed by spiking a 5 ng/mL standard into 100% serum. Serial dilutions of the spiked sample were prepared, and the percent recovery was calculated for each dilution relative to the expected concentration.
Dilution linearity
Recovery of Human FBLN7 was assessed by spiking a 5 ng/mL standard into 50% Cell Culture Supernatant. Serial dilutions of the spiked sample were prepared, and the percent recovery was calculated for each dilution relative to the expected concentration.
Serum levels in individuals
Duplicate measurements were performed on serum samples obtained from ten individual donors. Data are reported as dilution factor-corrected interpolated. The resultant mean FBLN7 concentration was 6.5 ng/mL, with a distribution spanning 5.4 to 8.1 ng/mL across the donor cohort.
Intra-Assay Precision (Precision within an assay)
Three samples of known concentration were tested fifteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays).
Three samples of known concentration were tested in separate assays to assess inter-assay precision. Assays were performed with at least three lots of components.
Determination of Minimum Detectable Dose (MDD)
The MDD was determined using three independent lots of assay components. For each lot, 19 replicate measurements of the diluent (zero calibrator) were performed. The mean (AVERAGE) and standard deviation (STDEV) of the 19 replicates were calculated. The MDD for each lot was then calculated according to the following formula:
MDD = 2 × STDEV + AVERAGE
Cross‑reactivity
The heatmap displays OD450 ratios for serum samples from multiple species. Color intensity is proportional to the O.D.450 ratio (test species / reference species). Darker colors indicate higher cross‑reactivity.
HOOK Effect Threshold
The upper limit of the HOOK effect was established at 100× the highest calibrator concentration (equivalent to a 2-log10 increase). No HOOK effect was observed below this threshold, confirming that samples within this concentration range yield reliable quantitative results without signal depression.
